Literature DB >> 7355758

Episodic drug treatment in the management of paroxysmal arrhythmias.

B Margolis, R A DeSilva, B Lown.   

Abstract

The use of maintenance medication in the treatment of episodic cardiac arrhythmia is often complicated by problems of patient compliance with therapy and adverse side effects. Furthermore, repeated hospitalizations and cardioversions are both costly and inconvenient. A method of intermittent drug therapy is described in which antiarrhythmic medication is taken only at the onset of an episode of arrhythmia. This approach was effective in terminating both supraventricular and ventricular arrhythmias in 24 of 32 patients and obviated the need for hospitalization and further treatment. In cases in which maintenance therapy was required because of the frequent occurrence of arrhythmia, periodic drug therapy was still of value in the treatment of breakthrough episodes. The use of intermittent drug therapy is a safe and effective approach to the management of episodic cardiac arrhythmia and, in addition, results in significant financial saving.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7355758     DOI: 10.1016/s0002-9149(80)80014-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  3 in total

1.  Absorption kinetics of oral and rectal flecainide in healthy subjects.

Authors:  L Lie-A-Huen; J H Proost; J H Kingma; D K Meijer
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Absorption kinetics and pharmacodynamics of two oral dosage forms of flecainide in patients with an episode of paroxysmal atrial fibrillation.

Authors:  V H M Deneer; L Lie-A-Huen; J H Kingma; J H Proost; S A Gossen; A Stuurman; G M M Uytdehaag; P H J M Dunselman; J R B J Brouwers
Journal:  Eur J Clin Pharmacol       Date:  2004-11-16       Impact factor: 2.953

3.  Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects.

Authors:  V H Deneer; L Lie-A-Huen; J H Kingma; J H Proost; J C Kelder; J R Brouwers
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.